Auna (AUNA) investor relations material

Executive summary

• Consolidated FX-neutral EBITDA grew 5% year-over-year, with all three geographies—Mexico, Colombia, and Peru—contributing to growth and all segments showing positive local currency results.

• Adjusted EBITDA decreased 3% as reported but margin remained flat at just over 22% YoY.

• Adjusted net income increased more than sixfold year-over-year, with positive net income for the sixth consecutive quarter.

• Revenue growth was led by Peru (+8% YoY), Mexico (+5% YoY in local currency), and stable performance in Colombia.

• The company remains optimistic about medium- to long-term growth despite near-term challenges in Mexico and Colombia.

Financial highlights

• Adjusted EBITDA rose 5% in FX-neutral terms but declined 3% as reported, with margin steady at just over 22%.

• Adjusted net income reached S/89 million, a sixfold increase YoY, driven by FX-neutral EBITDA growth and a positive FX variance.

• Free cash flow was $143M for the first six months, down from $155M last year, mainly due to non-recurring payments and collections timing.

• Cash position decreased 13% sequentially but remains healthy.

• Adjusted EPS was S/1.17 for the quarter.

Outlook and guidance

• Expect continued recovery in Mexico volumes as physician engagement improves.

• Peru anticipated to maintain strong growth and profitability as a key growth driver.

• Colombia to focus on risk-sharing models and payer diversification to safeguard cash flows.

• Continued expansion of oncology offerings in Mexico and further payor mix diversification in Colombia are planned.

• Near-term growth outlook is uncertain due to trade/tariff issues in Mexico and unresolved payer issues in Colombia.